Full specifications
BrivaracetamProduct specifications
Clinical Benefits
- Rapid and effective reduction of focal‑onset seizures.
- More selective and higher‑affinity binding to SV2A compared with levetiracetam, which may contribute to improved tolerability for some patients.
- Tablet formulation provides predictable pharmacokinetics and flexible dosing options (25–100 mg).
- Lower incidence of behavioral adverse effects than levetiracetam in many patients.
Specifications
- Absorption & Tmax
- Rapid; Tmax ~ 1 hour post-dose
- Plasma Protein Binding
- Very low (< 20%)
- Metabolism
- Amidase hydrolysis + CYP2C19 pathway
- Elimination Half-Life
- Approximately 9 hours
- Excretion
- Urine (>95%); feces (<1%)
- Pack
- 30 film-coated tablets per pack
Indications
| Indications | Adjunctive treatment of focal-onset seizures, with or without progression to bilateral tonic-clonic seizures, in patients aged 2 years and older. |
|---|
Warnings
| Warnings | Avoid alcohol. Rifampicin reduces exposure; consider dose adjustment when starting or stopping it. Carbamazepine-epoxide levels may rise. Strong CYP2C19 inhibitors and cannabidiol may increase exposure. |
|---|---|
| Pregnancy | use only when clinically necessary after assessing benefit and risk. Brivaracetam is excreted in breast milk; decide whether to discontinue breastfeeding or treatment. For healthcare professionals only. Consult locally approved Bricella prescribing information before use. |